Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-3500 + EBRT for Metastatic Disease
NCT05566574Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2022
- Primary completion
- Sep 2026
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of camonsertib in solid tumor, metastatic cancer, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2022; status: active, not recruiting.
02
Drugs
camonsertib
03
Conditions
solid tumormetastatic cancer
Beyond the preview
Go deeper on NCT05566574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05566574.